hmqPro Highly multiplexed, quantitative protein biomarker profiling (hmqPro)
- Coordinator
- Karolinska Institutet, Sweden
- Runs
- 1 July 2022 to 31 December 2023
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101069454
What the project is doing
In the project's own words, from its summary on CORDIS.
The project will develop a multipurpose, highly multiplexed, quantitative protein profiling (hmqPro) platform that can be adapted to a wide range of applications, particularly biomarker discovery. Biomarkers are a 43 Billion USD market spanning applications in diagnostics, drug discovery & development, personalized medicine, disease risk assessment. The method comprises an antibody-based profiling of a large number of proteins or protein posttranslational modifications against a large number of samples irrespective of source.
Unlike competitor methods, hmqPro does not require platform-specific assay or detection equipment. Dual multiplexing implemented in a variant method, hmqPro-2D, will make the platform competitive against existing protein profiling methods in per-assay cost, flexibility and scalability. The hmqPro platform uniquely complements the technology portfolio of Epigenica AB and we will chart out two commercialization routes: first, hmqPro will be integrated into a service laboratory offering high-throughput sample-to-result epigenome and protein profiling services to academia, pharma and biotech industries.
Second, we will package the method in a kit format distributed to R&D and clinical end users. In summary, the proposed project will deliver a new quantitative protein profiling platform that will have the capacity to impact the biomarker discovery market by combining unique flexibility with high-throughput.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Karolinska Institutet | Stockholm | Sweden | Coordinator |
| Epigenica AB | Stockholm | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI